Using an integrated approach combining mutational and copy number data, Banck et al. found that 33% of small intestinal NET patients showed PIK3/Akt/mTOR pathway alteration and 72% had therapeutically actionable genomic alterations. The gene discussed is MTOR; the disease is small intestine neuroendocrine neoplasm.